Long-Term Prognostic Value of High-Sensitivity Troponin T Added to N-Terminal Pro Brain Natriuretic Peptide Plasma Levels Before Valve Replacement for Severe Aortic Stenosis.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 12 2019
Historique:
received: 26 06 2019
revised: 12 09 2019
accepted: 12 09 2019
pubmed: 9 11 2019
medline: 2 4 2020
entrez: 9 11 2019
Statut: ppublish

Résumé

Natriuretic peptide plasma levels help to manage patients with severe aortic stenosis (AS). The role of troponin plasma levels in this patient cohort remains speculative. A consortium of 4 university hospital centers in Austria analyzed retrospectively 3,595 patients admitted for valve replacement because of severe AS since 2007. The aim was to compare the additive preprocedural value of high-sensitivity troponin T (hsTnT) to N-terminal pro brain natriuretic peptide (NT-proBNP) plasma levels in predicting postoperative long-term survival in a large cohort undergoing either surgical (57.8%) or transcatheter (42.2%) aortic valve replacement. During a median follow-up of 2.93 (1.91 to 4.92) years, 919 patients (25.6%) died, in them 556 (15.5%) due to cardiovascular causes. Both normal hsTnT (<14 ng/l) and NT-proBNP (within age- and sex-corrected normal range) plasma levels were found in 481 patients (14.3%, group 1). Normal hsTnT but elevated NT-proBNP plasma levels were found in 748 patients (22.3%, group 2). Elevated hsTnT but normal NT-proBNP plasma levels were found in 258 patients (7.7%, group 3). Both elevated hsTnT and elevated NT-proBNP plasma levels were found in 1,869 patients (55.7%, group 4). Using Log Rank tests for comparison there was a highly significant difference in both cardiovascular mortality (p <0.0001) and all-cause mortality (p <0.0001). All-cause mortality rates after 1, 3, and 5 years were 2.1%, 5.4%, 7.7% in group 1; 4.0%, 7.5%, 11.5% in group 2; 5.8%, 8.9%, 14.0% in group 3; and 12.3%, 22.6%, 28.4% in group 4. In conclusion, hsTnT adds additional impact to NT-proBNP as a routinely available biomarker for risk stratification concerning postoperative survival in patients with severe AS admitted for valve replacement. The present study supports the concept to integrate hsTnT plasma levels in the management of severe AS.

Identifiants

pubmed: 31699359
pii: S0002-9149(19)31052-5
doi: 10.1016/j.amjcard.2019.09.014
pii:
doi:

Substances chimiques

Biomarkers 0
Peptide Fragments 0
Troponin T 0
pro-brain natriuretic peptide (1-76) 0
Natriuretic Peptide, Brain 114471-18-0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1932-1939

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Fabian Barbieri (F)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Thomas Senoner (T)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Agne Adukauskaite (A)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Stephan Dobner (S)

Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.

Johannes Holfeld (J)

University Clinic of Heart Surgery, Medical University Innsbruck, Innsbruck, Austria.

Severin Semsroth (S)

University Clinic of Heart Surgery, Medical University Innsbruck, Innsbruck, Austria.

Thomas Lambert (T)

Department of Cardiology, Kepler University Hospital, Medical Faculty, Johannes Kepler University Linz, Austria.

David Zweiker (D)

Department of Internal Medicine, Division of Cardiology, Medical University Graz, Graz, Austria.

Thomas Theurl (T)

University Clinic of Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.

Peter Paul Rainer (PP)

Department of Internal Medicine, Division of Cardiology, Medical University Graz, Graz, Austria.

Albrecht Schmidt (A)

Department of Internal Medicine, Division of Cardiology, Medical University Graz, Graz, Austria.

Gudrun Maria Feuchtner (GM)

University Clinic of Radiology, Medical University Innsbruck, Innsbruck, Austria.

Clemens Steinwender (C)

Department of Cardiology, Kepler University Hospital, Medical Faculty, Johannes Kepler University Linz, Austria.

Uta Charlotte Hoppe (UC)

University Clinic of Internal Medicine II, Paracelsus Medical University, Salzburg, Austria.

Florian Hintringer (F)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Axel Bauer (A)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Silvana Müller (S)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria.

Michael Grimm (M)

University Clinic of Heart Surgery, Medical University Innsbruck, Innsbruck, Austria.

Bernhard Erich Pfeifer (BE)

Institute of Clinical Epidemiology, Tirol Kliniken, Innsbruck, Austria; Institute of Electrical and Biomedical Engineering, University for Health Sciences, Medical Informatics and Technology (UMIT), Hall in Tirol, Austria.

Wolfgang Dichtl (W)

University Clinic of Internal Medicine III, Medical University Innsbruck, Innsbruck, Austria. Electronic address: dichtl@me.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH